Arcturus Therapeutics (ARCT) Tops Q4 EPS by 63c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q4 EPS of ($0.32), $0.63 better than the analyst estimate of ($0.95). Revenue for the quarter came in at $33.99 million versus the consensus estimate of $42.54 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Zumiez, Inc. (ZUMZ) Misses Q2 EPS by 6c, Misses on Revenue; Offers Q3 Guidance
• Dexcom names former Stryker CFO Glenn Boehnlein to its board